Last updated: 2026-10-08 21:16:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Cardio Diagnostics Holdings Inc. (CDIO) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $1.86, with a market capitalisation of $5.92M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $7.91. This page covers its latest market performance, valuation, price trends and company information.
$5.92M | |
$1.99 | |
$255.00 | |
$0.97 | |
$1.96 | |
52.53K | |
56.09K | |
-- | |
$7.91 | |
$0.97 | |
-- | |
-- |
Cardio Diagnostics Holdings Inc. (CDIO) is trading at $1.97 in after-hours trading as of 2026-10-08 21:15:00, up 0.26% ($0.01) from the regular-session close of $1.96.
After-hours trading shows how investors are pricing CDIO after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Cardio Diagnostics Holdings Inc. (CDIO) moved from $1.87 to $1.86, representing a decline of 0.80% ($0.02).
The stock traded between $1.85 and $2.23 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 29.41 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 12.8%
CDIO is currently trading at $1.86, placing it 12.8% of the way from its 52-week low of $0.97 to its 52-week high of $7.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardio Diagnostics Holdings Inc. (CDIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.